Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Proto Labs IncPRLB · Entity 4553 | VP and Mng Director-PL Europe | February 13, 2024 | February 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Proto Labs Inc
Report date February 13, 2024 · Filed February 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,046 |
Ending reported balance
After 2024-02-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-13 · Tax withholding · Disposed 1,741 · Balance 16,333 Row 2 · 2024-02-13 · Grant · Acquired 6,713 · Balance 23,046 F1: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.52 · Expires 2034-02-13 | Direct | 6,182 |
Reported balance
After 2024-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-13 · Grant · Acquired 6,182 · Balance 6,182 F2: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested.
F2: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 15, 2024 22:08 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 6,182 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001437749-24-004402 · rdgdoc.xml · derivative · entry 3 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,182 Underlying: Common Stock · 6,182 shares Expires 2034-02-13 F2 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:08 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 6,713 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004402 · rdgdoc.xml · nonDerivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,046 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2025, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 22:08 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 1,741 | $33.52 | $58,358.32 |
DisclosureSEC source: 0001437749-24-004402 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,333 Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 3,048 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · derivative · entry 5 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,048 Underlying: Common Stock · 3,048 shares Expires 2026-02-14 F4 · derivative.exercise_date: The stock option vests in full on February 13, 2024. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 6,310 | $0.00 Strike: $33.84 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · derivative · entry 4 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,310 Underlying: Common Stock · 6,310 shares Expires 2033-02-14 F3 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantPerformance Stock Units · Derivative | 3,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · derivative · entry 3 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,325 Underlying: Common Stock · 3,325 shares Expires 2025-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 21:05 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 6,649 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · nonDerivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,074 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2024, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:05 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 1,119 | $34.23 | $38,303.37 |
DisclosureSEC source: 0001437749-23-003511 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,425 Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:07 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantPerformance Stock Units · Derivative | 1,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-003678 · rdgdoc.xml · derivative · entry 3 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,894 Underlying: Common Stock · 1,894 shares Expires 2024-12-31 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of Proto Labs, Inc. common stock. The performance stock units vest upon Proto Labs, Inc. common stock achieving a specified price per share. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:07 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 4,042 | $0.00 Strike: $59.40 | $0.00 |
DisclosureSEC source: 0001437749-22-003678 · rdgdoc.xml · derivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,042 Underlying: Common Stock · 4,042 shares Expires 2032-02-13 F2 · derivative.exercise_date: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:07 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 3,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-003678 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,544 F1 · shares: Restricted Stock Units that vest as follows: 25% of shares subject to the award will vest on February 13, 2023, and on each February 13th thereafter until all shares subject to the award are fully vested. Read SEC document |
| February 13, 2022 Filed Feb 15, 2022 21:01 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 728 | $56.34 | $41,015.52 |
DisclosureSEC source: 0001437749-22-003407 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,756 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:41 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 1,826 | $0.00 Strike: $180.46 | $0.00 |
DisclosureSEC source: 0001437749-21-003285 · rdgdoc.xml · derivative · entry 3 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,826 Underlying: Common Stock · 1,826 shares Expires 2031-02-16 F2 · derivative.exercise_date: The option vests as to 25% of the shares in four annual installments beginning on February 13, 2022. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:41 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 2,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-003285 · rdgdoc.xml · nonDerivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,484 F1 · shares: The restricted stock units vest as to 25% of the shares in four annual installments beginning on February 13, 2022. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:41 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 455 | $197.05 | $89,657.75 |
DisclosureSEC source: 0001437749-21-003285 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,119 Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 21:19 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 489 | $136.34 | $66,670.26 |
DisclosureSEC source: 0001437749-20-024773 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,574 Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:18 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 212 | $100.00 | $21,200.00 |
DisclosureSEC source: 0001437749-20-002909 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,063 Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:30 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 2,445 | $0.00 Strike: $96.72 | $0.00 |
DisclosureSEC source: 0001437749-20-002461 · rdgdoc.xml · derivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,445 Underlying: Common Stock · 2,445 shares Expires 2030-02-10 F2 · derivative.exercise_date: The option vests as to 25% of the shares in four annual installments beginning on February 13, 2021. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:30 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 2,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-002461 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,275 F1 · shares: The restricted stock units vest as to 25% of the shares in four annual installments beginning on February 13, 2021. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:31 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 477 | $95.83 | $45,710.91 |
DisclosureSEC source: 0001437749-19-023808 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,227 Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:06 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantEmployee Stock Option (right to buy) · Derivative | 2,136 | $0.00 Strike: $104.99 | $0.00 |
DisclosureSEC source: 0001437749-19-002459 · rdgdoc.xml · derivative · entry 2 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,136 Underlying: Common Stock · 2,136 shares Expires 2029-02-11 F2 · derivative.exercise_date: The option vests as to 25% of the shares in four annual installments beginning on February 13, 2020. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:06 UTC | Proto Labs Inc PRLB · Entity 4553 | GrantCommon Stock | 1,886 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-002459 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,704 F1 · shares: The restricted stock units vest as to 25% of the shares in four annual installments beginning on February 13, 2020. Read SEC document |
| December 01, 2018 Filed Dec 20, 2018 18:11 UTC | Proto Labs Inc PRLB · Entity 4553 | Tax withholdingCommon Stock | 477 | $126.93 | $60,545.61 |
DisclosureSEC source: 0001437749-18-022354 · rdgdoc.xml · nonDerivative · entry 1 Klaas Bjoern · CIK 0001732855 · VP and Mng Director-PL Europe 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,818 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.